<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942023000300001</article-id>
<article-id pub-id-type="doi">10.30827/ars.v64i3.27735</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estrategias para detectar necesidades farmacoterapéuticas y educacionales de pacientes con riesgo cardiovascular en farmacia comunitaria]]></article-title>
<article-title xml:lang="en"><![CDATA[Strategies for detecting pharmacotherapeutic and educational needs of patients with cardiovascular risk in community pharmacy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buenavida-Jurado]]></surname>
<given-names><![CDATA[Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De la Matta-Martín]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín-Calero]]></surname>
<given-names><![CDATA[Mª José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De la Puerta-Vázquez]]></surname>
<given-names><![CDATA[Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Farmacia Comunitaria  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Sevilla Facultad de Farmacia Departamento de Farmacología]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>64</volume>
<numero>3</numero>
<fpage>192</fpage>
<lpage>204</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942023000300001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942023000300001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942023000300001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Las enfermedades cardiovasculares son la principal causa de mortalidad.Desde la farmacia comunitaria (FC) es posible ayudar a los pacientes a mejorar los factores de riesgo cardiovascular (FRCV) modificables: hipertensión arterial (HTA), dislipemia, diabetes mellitus (DM), tabaquismo y obesidad. Entre los servicios profesionales farmacéuticos relacionados con la salud comunitaria se incluyen este tipo de actuaciones. El objetivo de este estudio ha sido determinar el perfil sociosanitario y farmacoterapéutico de los pacientes con RCV atendidos en la FC española, con el fin de diseñar la intervención más efectiva para ellos.  Método: Se realizó un estudio descriptivo de corte transversal entre enero 2017 y febrero 2018. Utilizando un formulario de recogida de datos se registraron los correspondientes a los pacientes de cuatro FC, dos en Sevilla y dos en Badajoz (España) mediante entrevistas individualizadas.  Resultados: La muestra inicial (n=100) quedó reducida a 98 pacientes, mayores (61,5±10,1 años), 51,0 % varones, con bajo nivel educativo (53,1 %) y la mayoría de ellos viviendo acompañados (87,8 %). El 74,5 % eran pacientes en prevención primaria y su nivel de RCVmoderado (2,51±1,89). HTA (83,7 %), dislipemia (64,39 %), diabetes II (38,8 %) y obesidad (52,0 %) fueron los factores más prevalentes. Casi la mitad de los pacientes (48,5 %) realizaban ejercicio físico regularmente y el 23,5 % eran fumadores. Los fármacos más consumidos fueron los modificadores de lípidos (59,4 %), antidiabéticos orales (37,5 %), antitrombóticos (32,2 %) y betabloqueantes (28,1 %),  Conclusiones: La utilización de formularios encaminados a detectar las necesidades educacionales y farmacoterapéuticas de pacientes con RCV, permitirá establecer diferentes estrategias para mejorar la capacidad de gestionar su enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Cardiovascular diseases are the leading cause of mortality, and community pharmacy (CP) can help patients improve modifiable cardiovascular risk factors (CVRF): hypertension (HT), dyslipidaemia, diabetes mellitus (DM), smoking, and obesity. Professional pharmaceutical services related to community health include this type of action. The aim of this study was to determine the socio-health and pharmacotherapeutic profile of patients with CVR treated in Spanish CP, to design the most effective intervention for them.  Method: A descriptive cross-sectional study was conducted between January 2017 and February 2018. Using a data collection form, data from patients in four CP, two in Seville and two in Badajoz (Spain) were recorded through individualised interviews.  Results: The initial sample (n=100) was reduced to 98 patients, older (61.5±10.1 years), 51.0 % male, with low educational level (53.1 %) and most of them living accompanied (87.8 %). 74.5 % were patients in primary prevention and their CVR level was moderate (2.51±1.89). Hypertension (83.7 %), dyslipidaemia (64.39 %), diabetes II (38.8 %) and obesity (52.0 %) were the most prevalent factors. Almost half of the patients (48.5 %) exercised regularly and 23.5 % were smokers. The drugs most commonly used were lipid modifiers (59.4 %), oral antidiabetics (37.5 %), antithrombotics (32.2 %) and beta-blockers (28.1 %).  Conclusions: The use of forms aimed at detecting the educational and pharmacotherapeutic needs of CVR patients will allow one to establish different strategies to improve their ability to manage their disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Farmacia Comunitaria]]></kwd>
<kwd lng="es"><![CDATA[Riesgo Cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[Necesidades Educacionales]]></kwd>
<kwd lng="es"><![CDATA[Servicios Profesionales Farmacéuticos]]></kwd>
<kwd lng="en"><![CDATA[Community Pharmacy]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular Risk]]></kwd>
<kwd lng="en"><![CDATA[Educational Needs]]></kwd>
<kwd lng="en"><![CDATA[Professional Pharmaceutical Services]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organitation</collab>
<source><![CDATA[Technical package for cardiovascular disease management in primary health care]]></source>
<year>2016</year>
<publisher-name><![CDATA[Ediciones de la OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[Defunciones según la causa de muerte]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celentano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Panico]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palmieri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Guillaro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brancati]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[di Palma Esposito]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citizens and family doctors facing awareness and management of traditional cardiovascular risk factors: results from the Global Cardiovascular Risk Reduction Project (Help Your Heart Stay Young Study)]]></article-title>
<source><![CDATA[Nutr Metab Cardiovasc Dis]]></source>
<year>2003</year>
<volume>13</volume>
<page-range>211-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frijling]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Keus]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Jenks]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Akkermans]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Hulscher]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perceptions of cardiovascular risk among patients with hypertension or diabetes]]></article-title>
<source><![CDATA[Patient Educ Couns]]></source>
<year>2004</year>
<volume>52</volume>
<page-range>47-53</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Borch-Johnsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Boysen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Burell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cifkova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2007</year>
<volume>28</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2375-414</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>Foro de Atención Farmacéutica en farmacia Comunitaria</collab>
<article-title xml:lang=""><![CDATA[Quinto Comunicado. Cartera de Serviciuos Farmacéuticos en la Farmacia Comunitaria]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>2012</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Foro de AF-FC</collab>
<source><![CDATA[Servicios Profesionales Farmacéuticos Asistenciales]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín-Calero]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[de la Matta]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Luís]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La caracterización de pacientes como herramienta útil para ofrecer servicios personalizados en farmacia comunitaria]]></article-title>
<source><![CDATA[Farmacéuticos Comunitarios]]></source>
<year>2015</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>5-17</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fliefel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tröltzsch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kühnisch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrenfeld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Otto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review]]></article-title>
<source><![CDATA[Int J Oral Maxiliofac Surg]]></source>
<year>2015</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>568-85</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>SEMG</collab>
<source><![CDATA[Modelo de coordinación médico-farmacéutico para la atención al paciente con enfermedad crónica en atención primaria]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spiering]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[AgabitiRosei]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azizi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2019</year>
<volume>72</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>160.e1-160.e78</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Koskinas]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Casula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Badimon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<page-range>111-88</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Handelsman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bloomgarden]]></surname>
<given-names><![CDATA[ZT]]></given-names>
</name>
<name>
<surname><![CDATA[Grunberger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Umpierrez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Association of Clinical Endocrinologists and American College of Endocrinology- Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2015</year>
<volume>21</volume>
<numero>suppl 1</numero>
<issue>suppl 1</issue>
<page-range>1-87</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Sociedad Española para el Estudio de la Obesidad</collab>
<source><![CDATA[IMC]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[WHO Guidelines on physical activity and sedentary behaviour]]></source>
<year>2022</year>
<publisher-name><![CDATA[Ediciones de la OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marques Santana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación de la efectividad de una intervención basada en la gestión de la farmacoterapia asociada a la educación terapéutica en pacientes de riesgo cardiovascular]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Sevilla ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Sevilla]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morisky]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concurrent and predictive validity of a self-reported measure of medication adherence]]></article-title>
<source><![CDATA[Med Care]]></source>
<year>1986</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-74</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Asociación Médica Mundial</collab>
<source><![CDATA[Declaración de Helsinki. Investigación médica en seres humanos]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogunsina]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dibaba]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Akinyemiju]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between life-course socio-economic status and prevalence of cardio-metabolic risk factors in five middle-income countries]]></article-title>
<source><![CDATA[J Glob Health]]></source>
<year>2018</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Stappen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Latomme]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cardon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Bourdeaudhuij]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lateva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chakarova]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Barriers from Multiple Perspectives Towards Physical Activity, Sedentary Behaviour, Physical Activity and Dietary Habits When Living in Low Socio-Economic Areas in Europe. The Feel 4 Diabetes Study]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2018</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Braithwaite]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Akinyemiju]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socio-economic status over the life course and obesity: Systemic review and mea-analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Ference]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyungah]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. A Systematic Review and Meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>316</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1289-97</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chakraborty]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment and Diagnosis of Diabetes Mellitus and Its Complication: Advanced Approaches]]></article-title>
<source><![CDATA[Mini Rev Med Chem]]></source>
<year>2015</year>
<volume>15</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1132-3</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eid]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sas]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Abcouwer]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Pennathur]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insights into the mechanisms of diabetic complications: role of lipids and lipidmetabolism]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2019</year>
<volume>62</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1539-49</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuntz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lampert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socioeconomic factors and obesity]]></article-title>
<source><![CDATA[Dtsch Arztebl Int]]></source>
<year>2010</year>
<volume>107</volume>
<numero>30</numero>
<issue>30</issue>
<page-range>517-22</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allagbé]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Zeller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Airagnes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Limosin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Boussadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Risk Among Patients Who Smoke: Risk Profiles and Differences by Sex]]></article-title>
<source><![CDATA[Am J Prev Med]]></source>
<year>2022</year>
<volume>63</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>800-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Critchley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Capewell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>290</volume>
<page-range>86-97</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuevas Fernández]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias Girón]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Pérez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz Simarro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera de León]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre-Jaime]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del tabaquismo según clase social en la población adulta de las Islas Canarias durante el periodo 2000-2015: seguimiento de la cohorte CDC-Canarias]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2020</year>
<volume>52</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>381-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>SEFAC</collab>
<source><![CDATA[Una de cada cuatro personas que quiere dejar de fumar recurre al farmacéutico en su primer intento]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bofí Martínez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[García Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of health education and drug therapy monitoring interventions in patients with cardiovascular risk factors attending a community pharmacy (FISFTES-PM Study)]]></article-title>
<source><![CDATA[Aten primaria]]></source>
<year>2015</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>141-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsuyuki]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Al Hamarneh]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmelgarn]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: the Multicenter Randomized Controlled RxEACH Trial]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2016</year>
<volume>67</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2846-54</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Artés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martin Oliveros]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iracheta Todó]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Diego Colilla]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Sánez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Catalá Cerdan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical impact of a pharmaceutical profesional service intervention with or without a multi- compartment medication in non-adherent, uncontrolled, chronic hypertensive, polymedicated patients in spanish community pharmacies]]></article-title>
<source><![CDATA[SEFAC-SPD- VALOR STUDY]]></source>
<year>2018</year>
<volume>21</volume>
<numero>supl.3</numero>
<issue>supl.3</issue>
<page-range>S270-1</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filié Haddad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[SatieTakamiya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martins da Silva]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Barros Barbosa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología en la tercera edad: medicamentos de uso continuo y peligros de la interacción medicamentosa]]></article-title>
<source><![CDATA[Gerokomos]]></source>
<year>2009</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrera-Lasfuentes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Palacio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Clemente Roldán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Malo Fumanal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rabanaque Hernández]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de medicamentos en población adulta influencia del autoconsumo]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2013</year>
<volume>45</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>429-535</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Chamorro]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Chamorro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Merino]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto de la actuación farmacéutica en la adherencia del tratamiento farmacológico de pacientes ambulatorios con riesgo cardiovascular (EMDader-CV- Incumplimiento) Universidad de Granada]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2011</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>245-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
